



Press
Release

Vifor Pharma comments on media speculation

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

St. Gallen, Switzerland, 13 December 2021 – Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this. Until then, Vifor does not comment on these discussions.

Vifor Pharma nimmt Stellung zu Medienspekulationen

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

St. Gallen, Switzerland, 13 December 2021 - Vifor führt mit CSL Gespräche über eine mögliche Transaktion. Entsprechende Entscheide sind noch nicht gefallen, es gibt diesbezüglich auch keine zeitlichen Vorgaben. Bis dahin kommentiert Vifor diese Gespräche nicht.

Contact and further information:

Media Relations

Nathalie Ponnier

Global Head Corporate Communications

Investor Relations

Julien Vignot

Head of Investor Relations

+41 79 957 96 73

media@viforpharma.com

+41 58 851 66 90

investors@viforpharma.com

About Vifor Pharma Group

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

For more information, please visit viforpharma.com.